Latest news with #SAB
Daily Maverick
2 days ago
- Business
- Daily Maverick
SAB Joins Forces with SARU as Events Delivery Partner Across All Rugby Events
The South African Breweries (SAB) and the South African Rugby Union (SA Rugby) today announced the conclusion of a landmark long-term Event Partnership Agreement which sees SAB become the official and exclusive event delivery partner for all SA Rugby events. This partnership means that SAB will work closely with SA Rugby to plan and deliver all Springbok Test Matches hosted on home soil, from in-stadium activations to fan experiences outside of the stadium. Through this collaboration, SAB and SA Rugby aim to broaden access to rugby, bringing the spirit and excitement of rugby to more South Africans. Commenting on the partnership, SAB CEO Richard Rivett-Carnac said, 'Beer and sports have always been synonymous with each other. Being a delivery events partner for SA Rugby will give much needed access to rugby games across the nation, showcasing our long-term commitment to sports. This milestone underscores our commitment to national pride and access to world-class rugby for all South Africans'. SAB will bring to life these events through its heritage brand Castle Lager – whose purpose has always been deeply rooted in our nation's sporting culture. The agreement is for an initial five-year term and will see SAB activate platforms such as, Castle Lager Boktown across the country to give access to the rugby experience to all South Africans. The Castle Lager Boktown platform will elevate the fan experiences, bringing South Africans together and amplify national pride. Commenting on the partnership, Rian Oberholzer, CEO of SA Rugby, said: 'We are delighted to broaden and deepen our relationship with SAB and Castle Lager. 'We have been partners for more than four decades and this arrangement takes us to the next level. It allows us to tap into SAB's event delivery experience to enhance the match-day experience for fans as well as reviving a communal experience for national team fans. 'The new Castle Lager Boktown will allow fans to taste the Test match vibe at the best seats NOT in the stadium and bring fans ever close to the game day experience.' Springboks Elrigh Louw, Ruan Nortje and Morne van den Berg were in attendance to champion this partnership when the agreement was unveiled at the SAB Headquarters on Friday. From celebrated Springbok players and coaches to local personalities, these figures will bring the Castle Lager Boktown to life and deepen fan connections. 'We are celebrating more than a sponsorship; we are celebrating a shared national spirit.' said Mr Gayton McKenzie, Minister of Sports, Arts and Culture. 'The enduring relationship between Castle Lager and the South African Rugby Union reflects the kind of long-term, purposeful partnerships our sporting codes need. This commitment is a vote of confidence in our athletes, in our fans and the role that sport plays in unity, pride and social upliftment – the kind of partnerships that are based on consistency and a genuine passion for the game and our nation. It shows us what's possible when corporate and cultural leadership align.' The announcement event, attended by the Ministry of Sport, Arts, and Culture, SA Rugby executives, and senior SAB leadership, signalled a renewed call for inclusivity, legacy building and a future where everyone has access to sport. As SAB continues to commemorate its 130-year journey of commitment to South Africa, this partnership reinforces this commitment to building the nation. DM
The South African
2 days ago
- Health
- The South African
BEER problem: Fire breaks out at SAB in Soweto
The Johannesburg Emergency Services has responded to a fire incident at the South African Breweries (SAB) in Soweto, near South Gate. Emergency Medical Services (EMS) spokesperson Xolile Khumalo says the blaze reportedly began when the grass in a nearby field caught fire. She said the fire spread and ignited storage crates on the brewery's premises. When South Africans connect, we don't just network; we build a community. The Lekker Network is a professional network where every conversation starts with, 'How can I help you?' Come join us & be a part of a community of extraordinary Saffas. 'At this stage, no injuries have been reported. Emergency teams are working swiftly to contain the fire and prevent further damage,' said Khumalo. No injuries have been reported at the time of publishing. Khumalo warned residents to stay away from the area as a safety precaution. Let us know by leaving a comment below, or send a WhatsApp to 060 011 021 1 Subscribe to The South African website's newsletters and follow us on WhatsApp, Facebook, X and Bluesky for the latest news.
News24
2 days ago
- General
- News24
Fire put out at SAB Baragwanath depot in Soweto, no injuries reported
Firefighters have extinguished a blaze at the South African Brewery's (SAB) Baragwanath depot in Soweto. City of Johannesburg's EMS spokesperson Xolile Khumalo said the blaze reportedly began when grass in a nearby field caught fire. 'This soon spread quickly and ignited storage crates on the premises,' she said. 🚨 Fire Reported at SAB Baragwanath Depot 🔥 Our team is currently responding to the scene. Efforts are underway to assist and secure the area. Posted by Vision Tactical on Thursday, June 26, 2025 No injuries were reported. Khumalo said only the outdoor crate storage was affected. 'Fortunately, the structure on the premises was not affected by the blaze and remains unscathed,' Khumalo said. News24 has reached out to SAB to find out if any products have been affected. This comment will be added if received.
Business Wire
4 days ago
- Business
- Business Wire
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ('MAIA', the 'Company'), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (CST) in HCC and may participate in future investigator sponsored trials (IST). 'Drs. Pinato and Fulgenzi are scientific experts on inflammation as a pathogenic and prognostic mechanism in primary liver cancers. Together, their research has focused on improving the treatment of HCC, particularly with the use of anti-cancer immunotherapy,' said MAIA Chairman and CEO Vlad Vitoc, M.D. 'They will bring a wealth of knowledge to our SAB, with specialized expertise that will inform our plans and preparations for our upcoming clinical program in HCC. 'By the end of this year, we expect to have all required approvals to begin enrolling patients in a HCC trial,' Dr. Vitoc added. MAIA was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for ateganosine as a treatment for HCC in 2022. ODDs can provide up to seven years of market exclusivity. Dr. David Pinato is a clinician scientist in the Department of Surgery and Cancer at Imperial College London and a consultant oncologist at Imperial College Healthcare NHS Trust. As Director of Developmental Cancer Therapeutics at Imperial College, he leads a translational research program focused on the early clinical implementation of novel experimental anticancer therapies with particular emphasis on anti-cancer immunotherapy. Dr. Pinato's research efforts in liver cancer have been recognized by the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC). He has received awards by the British Society of Pharmacology and the Royal Society of Medicine, and fellowships by the European School of Oncology and Fulbright Program. Dr. Pinato completed his core medical training across some of the busiest acute hospitals in London and was elected to the Royal College of Physicians (MRCP). His research has been published in leading journals in the field including the Journal of Clinical Oncology, Annals of Oncology, Hepatology and many others. Dr. Pinato lectures internationally in the field of molecular oncology with a specific interest in HCC and acts as a reviewer for several peer-reviewed journals including The Lancet, Cancer Discovery, Hepatology and Journal of Hepatology. Dr. Claudia Fulgenzi is a specialist in medical oncology at Imperial College London, with dedicated professional interest in the field of immune-oncology and gastro-intestinal cancers, particularly hepatic-biliary malignancies. Dr. Fulgenzi graduated in medicine from the University of Rome Tor Vergata and subsequently specialized in medical oncology at the University Campus Bio Medico of Rome, Italy. Her contributions to the field have been recognized with prestigious awards including the ASCO Merit Award, the Young Investigator award by the International Liver Cancer Association (ILCA) and the American Society of Clinical Oncology. Dr. Fulgenzi is actively engaged in clinical practice in London, serving as an honorary consultant in oncology at Chelsea and Westminster Hospital and as a specialty doctor in the early phase clinical trial unit at Hammersmith Hospital. In these capacities, she conducts clinical and translational research, contributes to clinical trial design, and provides expert medical guidance to cancer patients. Hepatocellular carcinoma is the most frequently occurring primary liver tumor representing approximately 90% of all liver cancers. HCC currently ranks 5th by incidence and 3rd by mortality on a global scale. About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as 'may,' 'might,' 'will,' 'should,' 'could,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, 'MAIA,' 'Company,' 'we,' 'our,' and 'us' refers to MAIA Biotechnology, Inc. and its subsidiaries.
Business Recorder
5 days ago
- Business
- Business Recorder
SAB okays 0.5 MT import of sugar
ISLAMABAD: The Sugar Advisory Board (SAB) on Monday okayed the import of 0.5 million tons of sugar after the government exported the commodity in a large quantity in the current financial year, which led to a sharp increase in domestic sugar prices. The meeting of the SAB, which met with Federal Minister for National Food Security and Research Rana Tanveer Hussain, approved the import of 0.5 million of sugar to control rising prices and ensure a consistent supply of the commodity in the market. According to the Pakistan Bureau of Statistics (PBS), the country exported 765,734 metric tons of sugar between July and May this fiscal year, earning Rs114 billion. However, as expected following this export domestic sugar prices rose sharply and hit a record Rs190 per kg. Import of 250,000MT raw sugar: policy to be submitted to Cabinet During the meeting, the minister said that the decision to import sugar had become unavoidable due to a nationwide shortfall in supply and sharp price hikes. He attributed the recent surge in sugar prices largely to unjustified price increases by sugar mill owners. The minister emphasised that all formalities regarding the import will be completed within the next few days, and the imported sugar will be brought into the market at the earliest to provide relief to consumers. To tackle the crisis, the government has already initiated urgent measures and decided to implement strict monitoring of both sugar supply and pricing across the country. 'The situation demands immediate action. Stabilising sugar prices and ensuring its availability is the government's top priority,' said the minister. Copyright Business Recorder, 2025
